This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
Human PSMA / FOLH1 Protein, His Tag (active enzyme, MALS verified)
catalog :
PSA-H52H3
quantity :
1 mg, 100 ug
price :
2800 USD, 440 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
PSA-H52H3
product name :
Human PSMA / FOLH1 Protein, His Tag (active enzyme, MALS verified)
quantity :
1 mg, 100 ug
price :
2800 USD, 440 USD
quantity & price :
$440/100ug,$2800/1mg
target :
PSMA
host species :
Human
By Tag :
His Tag
Research :
For Research Use Only
Source :
Human PSMA, His Tag (PSA-H52H3) is expressed from human 293 cells (HEK293). It contains AA Lys 44 - Ala 750 (Accession # Q04609-1).
Endotoxin :
Less than 1.0 EU per μg by the LAL method.
Purity :
>95% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Human PSMA, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Formulation :
Supplied as 0.2 μm filtered solution in MES and NaCl with trehalose as protectant. Contact us for customized product form or formulation.
Storage :
Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● The product MUST be stored at -70°C or lower upon receipt;
● -70℃ for 3 months under sterile conditions.
Background :
Prostate-specific membrane antigen (PSMA) is also known as Folate hydrolase 1 (FOLH1), Glutamate carboxypeptidase 2 (GCP2), N-acetylated-alpha-linked acidic dipeptidase I (NAALAD1), which belongs to the peptidase M28 family and M28B subfamily. FOLH1 / PSMA is stable at pH greater than 6.5. FOLH1 / PSMA is a type II transmembrane zinc metallopeptidase that is most highly expressed in the nervous system, prostate, kidney, and small intestine. FOLH1 / GCP-2 is homodimer and binds 2 zinc ions per subunit, and required for NAALADase activity. The catalytic activity of PSMA involved in releasing of an unsubstituted, C-terminal glutamyl residue, typically from Ac-Asp-Glu or folylpoly – gamma - glutamates. FOLH1 / GCP-2 / PSMA has both folate hydrolase and N – acetylated – alpha – linked - acidic dipeptidase (NAALADase) activity and has a preference for tri-alpha-glutamate peptides. GCP-2 / PSMA involved in prostate tumor progression and also exhibits a dipeptidyl-peptidase IV type activity. In vitro, cleaves Gly-Pro-AMC.
References :
(1) Grauer L.S., et al., 1998, Cancer Res. 58:4787-4789.
(2) Mesters J.R., et al., 2006, EMBO J. 25:1375-1384.
(3) Barinka C., et al., 2009, J. Med. Chem. 50:3267-3273.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments